Shanghai Runda Medical Technology Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Shanghai Runda Medical Technology prognostiziert ein Gewinnwachstum at 94.6% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 95.3% pro Jahr.

Wichtige Informationen

94.6%

Wachstumsrate der Gewinne

95.3%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	31.6%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	20 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Earnings Tell The Story For Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) As Its Stock Soars 39%

Oct 22

These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively

Oct 18

Shanghai Runda Medical Technology (SHSE:603108) Has A Somewhat Strained Balance Sheet

Jun 26

Shanghai Runda Medical Technology Co., Ltd.'s (SHSE:603108) Earnings Haven't Escaped The Attention Of Investors

Jun 04

Does Shanghai Runda Medical Technology (SHSE:603108) Deserve A Spot On Your Watchlist?

Mar 21

Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) Stock Rockets 31% But Many Are Still Ignoring The Company

Mar 04

These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively

Feb 27

Gewinn- und Umsatzwachstumsprognosen

SHSE:603108 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2024	8,433	40	455	754	N/A
6/30/2024	8,761	190	513	802	N/A
3/31/2024	9,042	215	525	819	N/A
12/31/2023	9,147	273	410	730	N/A
9/30/2023	9,751	395	191	452	N/A
6/30/2023	10,255	433	-411	-139	N/A
3/31/2023	10,504	457	-499	-225	N/A
12/31/2022	10,494	418	-701	-429	N/A
9/30/2022	9,854	365	-577	-266	N/A
6/30/2022	9,378	336	-172	155	N/A
3/31/2022	9,008	332	-61	240	N/A
12/31/2021	8,860	380	70	371	N/A
9/30/2021	8,784	416	-236	122	N/A
6/30/2021	8,369	422	-123	244	N/A
3/31/2021	7,790	388	34	398	N/A
12/31/2020	7,069	330	-8	323	N/A
9/30/2020	6,784	253	-23	249	N/A
6/30/2020	6,700	246	-86	162	N/A
3/31/2020	6,820	273	-333	-61	N/A
12/31/2019	7,052	310	-42	247	N/A
9/30/2019	6,821	311	170	452	N/A
6/30/2019	6,464	292	204	481	N/A
3/31/2019	6,200	273	323	574	N/A
12/31/2018	5,964	262	274	539	N/A
9/30/2018	5,729	295	38	288	N/A
6/30/2018	5,351	267	N/A	167	N/A
3/31/2018	4,855	242	N/A	-6	N/A
12/31/2017	4,319	219	N/A	-88	N/A
9/30/2017	3,642	199	N/A	-169	N/A
6/30/2017	3,029	164	N/A	-152	N/A
3/31/2017	2,516	134	N/A	-171	N/A
12/31/2016	2,165	116	N/A	-125	N/A
9/30/2016	1,948	115	N/A	-96	N/A
6/30/2016	1,812	105	N/A	-228	N/A
3/31/2016	1,721	95	N/A	-205	N/A
12/31/2015	1,629	92	N/A	-227	N/A
9/30/2015	1,528	92	N/A	-101	N/A
6/30/2015	1,483	84	N/A	-22	N/A
3/31/2015	1,420	81	N/A	112	N/A
12/31/2014	1,359	75	N/A	36	N/A
12/31/2013	1,026	68	N/A	32	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 603108Das prognostizierte Gewinnwachstum (94.6% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 603108Die Erträge des Unternehmens (94.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (26.2% pro Jahr).

Hohe Wachstumserträge: 603108Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 603108 schneller wachsen werden als der Markt von CN.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von 603108 schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 603108 in 3 Jahren voraussichtlich hoch sein wird

Shanghai Runda Medical Technology Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Third quarter 2024 earnings released: CN¥0.061 loss per share (vs CN¥0.19 profit in 3Q 2023)

Earnings Tell The Story For Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) As Its Stock Soars 39%

These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively

New minor risk - Share price stability

Shanghai Runda Medical Technology Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 28%

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.16 in 2Q 2023)

Shanghai Runda Medical Technology Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Shanghai Runda Medical Technology (SHSE:603108) Has A Somewhat Strained Balance Sheet

Shanghai Runda Medical Technology Co., Ltd.'s (SHSE:603108) Earnings Haven't Escaped The Attention Of Investors

Shanghai Runda Medical Technology Co., Ltd., Annual General Meeting, May 23, 2024

Shanghai Runda Medical Technology Co., Ltd., Annual General Meeting, May 23, 2024

Shanghai Runda Medical Technology Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Does Shanghai Runda Medical Technology (SHSE:603108) Deserve A Spot On Your Watchlist?

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 15%

Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) Stock Rockets 31% But Many Are Still Ignoring The Company

These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively

Investor sentiment deteriorates as stock falls 16%

New minor risk - Shareholder dilution

Shanghai Runda Medical Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.25 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Shanghai Runda Medical Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.21 in 2Q 2022)

New minor risk - Dividend sustainability

Investor sentiment deteriorates as stock falls 23%

New major risk - Share price stability

Shanghai Runda Medical Technology Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 35%

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: CN¥0.72 (vs CN¥0.66 in FY 2021)

Investor sentiment improves as stock rises 24%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.20 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.66 (vs CN¥0.57 in FY 2020)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.15 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.05 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.57 (vs CN¥0.53 in FY 2019)

New 90-day low: CN¥10.36

New 90-day low: CN¥10.56

Investor sentiment improved over the past week

New 90-day low: CN¥11.50

New 90-day low: CN¥12.80

Third quarter earnings released

First half earnings released

New 90-day high - CN¥15.85

Shanghai Runda Medical Technology Co., Ltd. to Report Q2, 2020 Results on Aug 28, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken